Abstract
The adhesion capacities, transmigration capacities, and integrin expression of lymphocytes from patients with Guillain-Barré syndrome incubated with interferon-beta were studied. Interferon-beta induced a dose-dependent inhibition of lymphocyte adhesion to recombinant vascular adhesion molecule-1 (p < 0.0001) and recombinant intercellular adhesion molecule-1 (rICAM-1) (p < 0.01) without modulation of very late activation molecule-4 and lymphocyte function-associated antigen-1 expressions and a dose-dependent decrease of lymphocyte transmigration across fibronectin (p < 0.0001). Inhibition of adhesion to rICAM-1 was similar after long (18 hours) or short (5 minutes) incubation time. These results support the potential therapeutic benefit of interferon-beta in Guillain-Barré syndrome.
MeSH terms
-
Adjuvants, Immunologic / administration & dosage*
-
Cell Adhesion / drug effects
-
Cell Adhesion / immunology
-
Cell Movement / drug effects
-
Cell Movement / immunology
-
Dose-Response Relationship, Drug
-
Flow Cytometry
-
Guillain-Barre Syndrome / drug therapy*
-
Guillain-Barre Syndrome / immunology*
-
Humans
-
In Vitro Techniques
-
Integrin alpha4beta1
-
Integrins / analysis
-
Interferon-beta / administration & dosage*
-
Lymphocyte Function-Associated Antigen-1 / analysis
-
Lymphocytes / chemistry
-
Lymphocytes / cytology*
-
Receptors, Lymphocyte Homing / analysis
-
Vascular Cell Adhesion Molecule-1 / pharmacology
Substances
-
Adjuvants, Immunologic
-
Integrin alpha4beta1
-
Integrins
-
Lymphocyte Function-Associated Antigen-1
-
Receptors, Lymphocyte Homing
-
Vascular Cell Adhesion Molecule-1
-
Interferon-beta